Hints and tips:
...The closely watched fund invoked the wisdom of the recently retired University of Alabama American football coach Nick Saban, a repeat guest at its offices, to describe its zeitgeist....
...Richard Watts and Nick Williamson, the managers of the Chrysalis investment trust, are leaving asset management group Jupiter....
...Tuesday Australia, Tennis player and 2022 Wimbledon finalist Nick Kyrgios appears in court in Canberra charged with common assault Wednesday Niger, Independence Day holiday Thursday China, Qixi Festival...
...German drug and agrochemical conglomerate Bayer has also threatened to suspend crop sales to Russia next year unless it stops attacking Ukraine....
...Pharmaceuticals group Bayer, which manufactures two neonicotinoids previously used in the EU, said it would no longer sell these pesticides in the bloc....
...One thing to start: Bayer will pay up to $10.9bn to settle a wave of lawsuits over the potential carcinogenic effects of its pesticide product Roundup, relating to its takeover of US agrichemical company...
...Wednesday 14:00 GMT What’s happening ● Bayer slumped after the German chemicals group lost the first phase of the trial in the US over its glyphosate herbicide....
...Nick Giovanni, head of global technology, media and telecom investment banking at Goldman Sachs, says direct listings “should over the long term create more public companies”....
...The FT reported in September that Nick Read, then the incoming chief executive of Vodafone, had told investors he was considering a sale of the company’s directly controlled towers....
...Nick Read, who took over as chief executive last year, had previously said it could cover its dividend payment of €4.1bn a year after kicking off a cost reduction plan and indicating that it could sell its...
...His role will be split between Anthony Sweetman, current co-head of investment banking at UBS Australasia, and Nick Hughes, country operating officer UBS Australasia. More here....
...Robert Bayer and Ajay Singh have joined Macquarie Capital as senior managing directors in the industrials group. Bayer joins from Guggenheim Securities and Singh from UBS....
...Bayer (Q3) Investors will focus on the sales growth of Bayer’s bestselling drugs Xarelto and Eylea, while earnings from the newly acquired Monsanto business will play a lesser role due to the seasonality...
...Amadeus Capital Partners, a technology investor, has hired Nick Kingsbury and Volker Hirsch to its team of early-stage venture capital investors....
...Nick O’Grady and Bevis Metcalfe will join the banking and finance practice. They were formerly counsel at Ropes & Gray....
...Nick Zelenczuk, senior managing director and chief operations officer, will retire in May. Eric Wetlaufer, senior managing director and global head of public market investments, will be leaving in May....
...Neonicotinoids, chemically similar to nicotine, appeared to affect “far more species than we previously thought”, said study co-author Dr Nick Isaac of the UK’s Centre for Ecology and Hydrology, a research...
...Nick Kounis, head of macro research at ABN Amro also highlights “signs that the scope of the programme will be limited”....
...Nick Kounis, head of macro research at ABN Amro, also highlights “signs that the scope of the programme will be limited”....
...When Michael Kentschke, a financial controller with Bayer, in Germany, is preparing for a meeting he looks for an empty office with good soundproofing....
...“The lasting impact from today’s data may be dampened somewhat by proximity of the US elections and subsequent budget negotiations,” said Nick Bennenbroek, head of currency strategy at Wells Fargo Bank....
...However, it still looks a bit like the “tycoon tax” that Nick Clegg said he wanted last week – or even like Alternative Minimum Tax system from the US (which is supposed to prevent anyone paying income tax...
...The synthesis and mass-marketing of aspirin by Bayer of Germany at the end of the 19th century marked the birth of modern pharmaceuticals....
...In Frankfurt, shares in Bayer advanced on the back of trial results for a thrombosis drug. The large pharmaceutical group rose 3.4 per cent to €49.80, extending gains from the previous day....
...Magnesium producer K+S rose 4.3 per cent to €42.47, while Bayer added 3.8 per cent to €45.81....
International Edition